At the time of writing, MaxCyte Inc [MXCT] stock is trading at $1.55, down -4.91%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MXCT shares have gain 5.44% over the last week, with a monthly amount drifted -7.19%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MaxCyte Inc [NASDAQ: MXCT] stock has seen the most recent analyst activity on August 11, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, William Blair downgraded its rating to Mkt Perform on August 07, 2025. On July 22, 2025, Stephens initiated with a Overweight rating and assigned a price target of $6 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $7 on November 29, 2023. In a note dated August 24, 2021, Wedbush initiated an Outperform rating and provided a target price of $36 on this stock.
For the past year, the stock price of MaxCyte Inc fluctuated between $1.26 and $5.20. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. MaxCyte Inc [NASDAQ: MXCT] shares were valued at $1.55 at the most recent close of the market. An investor can expect a potential return of 287.1% based on the average MXCT price forecast.
Analyzing the MXCT fundamentals
According to MaxCyte Inc [NASDAQ:MXCT], the company’s sales were 34.42M for trailing twelve months, which represents an -16.35% plunge. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -1.45%, Pretax Profit Margin comes in at -1.33%, and Net Profit Margin reading is -1.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.24 and Total Capital is -0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5067 points at the first support level, and at 1.4633 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6067, and for the 2nd resistance point, it is at 1.6633.
Ratios To Look Out For
It is important to note that MaxCyte Inc [NASDAQ:MXCT] has a current ratio of 7.74. In addition, the Quick Ratio stands at 7.27 and the Cash Ratio stands at 0.81. Considering the valuation of this stock, the price to sales ratio is 4.80, the price to book ratio is 0.92.
Transactions by insiders
Recent insider trading involved Hemrajani Rekha, Director, that happened on Jun 25 ’25 when 10684.0 shares were sold. CHIEF FINANCIAL OFFICER, Swirsky Douglas J completed a deal on Aug 13 ’25 to buy 50000.0 shares. Meanwhile, President and CEO Masoud Maher bought 75000.0 shares on Aug 13 ’25.
